- Home
- VTVT vs ATNM Comparison
VTVT vs ATNM Comparison
Compare VTVT & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTVT
- ATNM
- Stock Information
- Founded
- VTVT 2015
- ATNM 2000
- Country
- VTVT United States
- ATNM United States
- Employees
- VTVT N/A
- ATNM N/A
- Industry
- VTVT Biotechnology: Pharmaceutical Preparations
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- VTVT Health Care
- ATNM Health Care
- Exchange
- VTVT Nasdaq
- ATNM Nasdaq
- Market Cap
- VTVT 54.4M
- ATNM 50.2M
- IPO Year
- VTVT 2015
- ATNM N/A
- Fundamental
- Price
- VTVT $31.31
- ATNM $1.34
- Analyst Decision
- VTVT Strong Buy
- ATNM Strong Buy
- Analyst Count
- VTVT 3
- ATNM 1
- Target Price
- VTVT $37.00
- ATNM $4.00
- AVG Volume (30 Days)
- VTVT 11.5K
- ATNM 250.0K
- Earning Date
- VTVT 11-06-2025
- ATNM 11-14-2025
- Dividend Yield
- VTVT N/A
- ATNM N/A
- EPS Growth
- VTVT N/A
- ATNM N/A
- EPS
- VTVT N/A
- ATNM N/A
- Revenue
- VTVT $17,000.00
- ATNM $90,000.00
- Revenue This Year
- VTVT N/A
- ATNM N/A
- Revenue Next Year
- VTVT N/A
- ATNM N/A
- P/E Ratio
- VTVT N/A
- ATNM N/A
- Revenue Growth
- VTVT N/A
- ATNM 11.11
- 52 Week Low
- VTVT $13.15
- ATNM $1.03
- 52 Week High
- VTVT $33.16
- ATNM $2.41
- Technical
- Relative Strength Index (RSI)
- VTVT 68.37
- ATNM 44.33
- Support Level
- VTVT $29.40
- ATNM $1.23
- Resistance Level
- VTVT $33.16
- ATNM $1.60
- Average True Range (ATR)
- VTVT 1.88
- ATNM 0.09
- MACD
- VTVT 0.34
- ATNM 0.01
- Stochastic Oscillator
- VTVT 74.76
- ATNM 24.32
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin, being investigated for the treatment of type 1 diabetes (T1D). Its product pipeline includes TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.